Dr. Tianwei Ma play a critical role to expand our product portfolio, and advance early R&D programs into clinical development. Dr. Tianwei Ma has more than 20 years of experiences in drug discovery focusing on medicinal chemistry, led many discoveries program to achieve PCC or IND stage and listed as an inventor or co-inventor for approximately 30 granted patents of applications.
During his PhD research, Dr. Ma participated in the early discovery of Clevudine (Levovir®), an anti-HBV agent. He then spent nearly 20 years at Eli Lilly & Company, where he contributed to the delivery of multiple small molecule clinical candidates, while advancing from principal research scientist to director of chemistry. Dr. Ma was also a Lilly certified Six Sigma Black Belt. After his tenure at Eli Lilly & Company, Dr. Ma has since served in critical roles for two biotech companies, PegBio & Company (Suzhou) and BioFront Therapeutics (Beijing) as VP, head of chemistry, responsible for building and leading the team, product and portfolio design, implementation, and progression.
Tianwei Ma obtained his PhD degree in medicinal chemistry from the University of Georgia, and he has a MSc. degree in medicinal chemistry from Peking University.